Biomarker: ALK

Crizotinib (Xalkori)

Targeted TherapyApproved for: NSCLCBiomarker: ALK, ROS1 Crizotinib (Xalkori) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive or ROS1 positive and has metastasized (spread to other parts of the body). Related Research News FDA Approves...
Read More
|
May 31, 2021
|
Treatment

Ceritinib (Zykadia)

Targeted TherapyApproved for: NSCLCBiomarker: ALK Ceritinib (Zykadia) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body). It is used in adults. Related Research...
Read More
|
May 31, 2021
|
Treatment

Ramucirumab (Cyramza)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR, ALK Ramucirumab (Cyramza) is a FDA-approved Targeted Therapy for non-small cell lung cancer (NSCLC) with the biomarker EGFR or ALK that has metastasized. It is used: With docetaxel in patients whose disease has gotten worse...
Read More
|
May 31, 2021
|
Treatment

Alectinib (Alecensa)

Targeted TherapyApproved for: NSCLCBiomarker: ALK Alectinib (Alecensa) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body). . Related Research News FDA Approves Repotrectinib...
Read More
|
May 31, 2021
|
Treatment

Lorlatinib (Lorbrena)

Targeted TherapyApproved for: NSCLCBiomarker: ALK Lorlatinib (Lorbrena) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body). It is used in patients whose disease got...
Read More
|
May 27, 2021
|
Treatment

Brigatinib (Alunbrig)

Targeted TherapyApproved for: NSCLCBiomarker: ALK Brigatinib (Alunbrig) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) with the biomarker that is ALK positive and has metastasized (spread to other parts of the body). It is used in...
Read More
|
May 27, 2021
|
Treatment

Ramucirumab (Cyramza)

Targeted TherapyApproved for: NSCLCBiomarker: EGFR, ALK Ramucirumab (Cyramza) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has metastasized. It is used: With erlotinib hydrochloride as first-line therapy in patients whose disease has certain mutations in the...
Read More
|
March 19, 2021
|
Treatment